Literature DB >> 10358203

IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder.

K Hong1, A Chu, B R Lúdvíksson, E L Berg, R O Ehrhardt.   

Abstract

The onset of acute psoriasis and the exacerbation of chronic psoriasis are often associated with a history of bacterial infection. We demonstrate that while only few scid/scid mice develop disease when CD4+CD45Rbhigh T cells are transferred alone, coadministration of LPS plus IL-12 or staphylococcal enterotoxin B into scid/scid mice 1 day after CD4+CD45Rbhigh T cell transfer greatly enhances disease penetrance and severity. Most importantly, the skin lesions induced by this method exhibit many of the histologic hallmarks observed in human psoriasis. Skin infiltrating CD4+ T cells were predominantly memory/effector cells (CD45Rblow) and exhibited a highly polarized Th1 phenotype. To test whether the development of pathogenic T cells was dependent on their production of IFN-gamma, we transferred IFN-gamma-/- CD4+CD45Rbhigh T cells into scid/scid or into T, B and NK cell-deficient scid/beige mice. Surprisingly, the incidence of psoriasis was similar to scid/scid animals that received IFN-gamma+/+ T cells, although acanthosis of the skin was attenuated. In contrast, the development of psoriasis was abolished if anti-IL-12 mAb was administered on day 7 and 35 after T cell transfer. Skin-derived IFN-gamma-/- inflammatory cells, but not cells from anti-IL-12-treated animals, secreted substantial amounts of TNF-alpha, suggesting that the inflammatory effect of IFN-gamma-/- T cells may be partly exerted by TNF-alpha and that the therapeutic effect of anti-IL-12 may depend on its ability to down-regulate both TNF-alpha and IFN-gamma. Overall, these results suggest that IL-12, independently of IFN-gamma, is able to induce pathogenic, inflammatory T cells that are able to induce psoriasiform lesions in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358203

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

2.  Ustekinumab.

Authors:  Kristian Reich; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

3.  CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin.

Authors:  Mingcan Xia; Shaomin Hu; Yaoyao Fu; Wensen Jin; Qiyi Yi; Yurika Matsui; Jie Yang; Mary Ann McDowell; Surojit Sarkar; Vandana Kalia; Na Xiong
Journal:  J Allergy Clin Immunol       Date:  2014-04-24       Impact factor: 10.793

4.  Noncanonical conformation of CDR L1 in the anti-IL-23 antibody CNTO4088.

Authors:  Alexey Teplyakov; Galina Obmolova; Alison Rogers; Gary L Gilliland
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-02-23

5.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

Review 6.  Cytokine-based therapy in psoriasis.

Authors:  Anupam Mitra; Robyn S Fallen; Hermenio Cavalcante Lima
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 7.  Role of immune-regulatory cells in skin pathology.

Authors:  Dan Ilkovitch
Journal:  J Leukoc Biol       Date:  2010-07-13       Impact factor: 4.962

8.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Authors:  Hak-Ling Ma; Spencer Liang; Jing Li; Lee Napierata; Tom Brown; Stephen Benoit; Mayra Senices; Davinder Gill; Kyriaki Dunussi-Joannopoulos; Mary Collins; Cheryl Nickerson-Nutter; Lynette A Fouser; Deborah A Young
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

9.  Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.

Authors:  Hermenio Cavalcante Lima; Alexandra Boer Kimball
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

10.  Ustekinumab in the therapy of chronic plaque psoriasis.

Authors:  Jenna L O'Neill; Robert E Kalb
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.